Sunday, February 10, 2008 7:49:59 PM
It should be noted that some of the various programs (if successful) could be used in combination as they work on various pathways. Also some programs may not be aimed at addressing disease progress but rather some of the associated ailments (e.g. Cough). Look for future updates and opinions on various programs would also appreciate others views/updates.
Phase 3
Pirfenidone (ITMN) - http://clinicaltrials.gov/ct2/show/NCT00287716 http://clinicaltrials.gov/ct2/show/NCT00287729 http://www.capacitytrials.com/wt/page/index
See InterMune board and RMF: http://investorshub.advfn.com/boards/board.asp?board_id=8637
Bosentan [Tracleer] (Actelion) - http://clinicaltrials.gov/ct2/show/NCT00391443 http://tinyurl.com/3akama
Phase 2 failed in their endpoint proceeding with Phase III (BUILD-3) 390 patients, event-driven study (131 events needed defined as decreased FVC and DLCO, acute exacerbation, or death interim analysis with 62 events) randomized 2:1.
Sildenafil (National Heart, Lung, and Blood Institute (NHLBI)/Pfizer) - http://clinicaltrials.gov/ct2/show/NCT00517933
Phase 2
Gleevec (Novartis) - http://clinicaltrials.gov/ct2/show/NCT00131274
QAX576 (Novartis) - http://clinicaltrials.gov/ct2/show/NCT00532233
Thalidomide (Johns Hopkins University/Celgene) - http://clinicaltrials.gov/ct2/show/NCT00162760 http://clinicaltrials.gov/ct2/show/NCT00600028
BIBF1120 (Boehringer Ingelheim) - http://clinicaltrials.gov/ct2/show/NCT00514683
Tetrathiomolybdate [Coprexa] (U of Michigan/Pipex) - http://clinicaltrials.gov/ct2/show/NCT00189176
Phase 1/Unsure
GC1008 (CAT/Genzyme) - http://clinicaltrials.gov/ct2/show/NCT00125385
FG-3019 (Fibrogen) http://clinicaltrials.gov/ct2/show/NCT00074698 http://www.fibrogen.com/uses/ipf.html
Remodulin (UTHR) – Unsure of current status have heard mention of using the Oral formulation [Though personally I would wonder why the inhaled would not be tried].
Inhaled Actimmune (Respironics/U of Michigan) - http://tinyurl.com/35fnuv http://tinyurl.com/2kbztr
Promedior – Company doing early stage research
Gilead/Parion - Licensing deal for pulmonary disease http://www.gilead.com/pr_1040975
FPT025 (FivePrime/J&J) - http://www.fiveprime.com/index.php?option=com_content&task=view&id=41&Itemid=75
Neopharm – Unclear if they are actually moving forward or just looking for some PR.
Immuneworks – Using immune tolerance
EmphyCorp – Working in Interstitial Lung Disease
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM